Search
for
Sort by
Research 121–150 of 1000+
- Repurposing DPP4-Inhibition to Improve Hair Follicle Activation and Regeneration
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination
- BH07 The socioeconomic burden of alopecia areata
- MCAS, POTS, Dysautonomia, and “Genetic Disorders” — Long COVID Observations
- BH23 Mind the gap! Navigating barriers to care access for patients with alopecia areata in the UK: a qualitative interview study
- Guest Editor's Note
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- First drug for severe alopecia recommended by NICE could benefit 14,000 patients
- Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Equity research
- Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production
- Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production
- Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production
- Pantolactams as androgen receptor antagonists for the topical suppression of sebum production
- Ritlecitinib: First Approval
- P063 Tracking down autoantibodies
- Hypertrichosis of the eyelashes caused by bimatoprost
- Rational Design and Synthesis of 4-((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
- A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States
- Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?
- Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States
- Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction
- Investigation of drug partition property in artificial sebum
- Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata
- The women’s hair growth questionnaire: Development and validation of a patient-reported measure for treatment efficacy in androgenetic alopecia